Arrakis - Arrakis Therapeutics
EXPLORE WHAT'S NEW. We are pioneering a new world of rSM medicines, ourselves and with partners. Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify …
Amgen and Arrakis Therapeutics Announce Multi-Target …
THOUSAND OAKS, Calif. and WALTHAM, Mass., Jan. 11, 2022 – Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and …
News Releases - Arrakis Therapeutics
Jan 10, 2022 · Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery …
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Waltham Biotech Arrakis lays off 20% of workforce – NBC Boston
Mar 4, 2024 · Arrakis Therapeutics parted ways with about 20% of its workforce last week. CEO Michael Gilman confirmed the layoffs to the Business Journal on Monday, writing in an …
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
Apr 8, 2020 · Arrakis now has a pipeline that includes potential drugs for cancer, neurological diseases, rare disorders, and dyslipidemia. The Roche deal is the company's first, but it marks …
Amgen, Arrakis partner to develop drugs that eliminate ... - STAT
Jan 11, 2022 · A mgen and the biotech startup Arrakis Therapeutics announced a research collaboration Tuesday to discover and develop a new class of oral drugs that selectively …
Arrakis Therapeutics signs drug discovery deal with Roche
Apr 9, 2020 · Arrakis Therapeutics has signed a collaboration and licence agreement with Roche to identify RNA-targeted small molecule (rSM) drugs against various targets in different …
Amgen taps Waltham biotech Arrakis Therapeutics for RNA …
Jan 11, 2022 · Arrakis and Amgen will work together to create small molecules that can bind to and degrade certain disease-causing RNAs. For Amgen, the deal marks an expansion.
Drugging RNA - Nature Biotechnology
May 17, 2023 · Ribometrix is primarily targeting mature mRNAs, again unspecified. Arrakis has disclosed its lead program, which targets the mature mRNA encoding the myc transcription …
- Some results have been removed